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Background: Cancer stem cells (CSCs) are thought to be a source of tumor recurrence due to their stem cell-like
properties. MicroRNAs (miRNAs) regulate both normal stem cells and CSCs, and dysregulation of miRNAs has an
important role in tumorigenesis. Cluster of differentiation (CD) 133+ and spheroid formation have been reported to
be one of the main features of ovarian CSCs. Therefore, we determined the miRNA expression profile of a CD133+
spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line.
Methods: Initially, we confirmed the enrichment of the OVCAR3 CD133 subpopulation by evaluating in vitro
anchorage-independent growth. After obtaining a subpopulation of CD133+ OVCAR3 cells with > 98% purity via cell
sorting, miRNA microarray and real-time reverse transcription-polymerase chain reaction (RT-PCR) were performed
to evaluate its miRNA profile.
Results: We found 37 differentially expressed miRNAs in the CD133+ spheroid-forming subpopulation of OVCAR3
cells, 34 of which were significantly up-regulated, including miR-205, miR-146a, miR-200a, miR-200b, and miR-3, and
3 of which were significantly down-regulated, including miR-1202 and miR-1181.
Conclusions: Our results indicate that dysregulation of miRNA may play a role in the stem cell-like properties of
ovarian CSCs.
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Epithelial ovarian cancer (EOC) is the most lethal of all
gynecologic malignancies. Although an initial treatment
method offers a response rate of 70%, most patients
eventually relapse with chemo-resistant disease [1].
Thus, identification of new molecular markers that tar-
get chemo-resistant disease is needed for therapeutic
approaches to ovarian cancer.
Cancer stem cells (CSCs) have recently been deter-
mined to comprise a small proportion of highly
malignant cancer cells possessing stem cell properties [2].
It is generally accepted that stem cells are more resistant* Correspondence: ytkchoi@yuhs.ac
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unrestricted use, distribution, and reproductioto apoptosis and DNA damage and are therefore more
likely to be resistant to chemotherapy [3]. As such, if CSCs
are refractory to therapy, they are unlikely to be curative
and relapse would be expected. Previous studies of acute
myelogenous leukemia (AML) provided compelling evi-
dence of the existence of CSCs [4]. Thereafter, several stu-
dies characterized CSCs in other types of tumors
including those of the brain, breast, colon, pancreas, pros-
tate, and ovaries.
Self-renewal and lineage capacity are the hallmarks of
any stem cell [2]. Therefore, a few methods have been
developed to use these characteristics in order to assay
cancer stem cells. The ability of cells to form tumor
spheres is one such method, evaluating the capacity of
cancer cells to grow as multi-cellular spheroids under
non-differentiating and non-adherent conditions [5].
Using this method, ovarian CSCs from patients withd; licensee BioMed Central Ltd. This is an Open Access article distributed under
n License (http://creativecommons.org/licenses/by/2.0), which permits
n in any medium, provided the original work is properly cited.
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cell-like properties is examined [6]. In addition, in vivo
serial transplantation assays, dye exclusion assays, and
isolation via cell surface specific antigen profile methods
are now used to identify CSCs. In ovarian cancer, the
most commonly used cell surface marker to identify
ovarian CSCs involves the use of cluster of differentia-
tion (CD) 133+ cell populations [7].
MicroRNAs (miRNAs) are 21–23 nucleotides long and
act as regulatory molecules by either inhibiting transla-
tion or promoting degradation of target mRNA tran-
scripts [8]. MiRNA-driven pathways are fundamental for
the maintenance and proper function of cell stemness in
embryonic stem cells. Biologically significant miRNA-
driven pathways in embryonic stem cells have also been
identified in CSCs and are speculated to be involved in
oncogenesis [9]. Recently, miR-200a was reported to be
down-regulated in CD133/1+ ovarian cancer stem cells
[10]. Likewise, CD44+ epithelial ovarian CSCs were
reported to have low levels of miR-199a and miR-214
[11]. Guo and colleagues reported that the expression
levels of miR-204, miR-206, miR-223, miR-9, miR-100,
and miR-200c were dysregulated in CD133+ OVCAR3
human ovarian cancer cells [12]. However, only limited
data are available regarding miRNA expression profiles
of ovarian CSCs.
In this study, miRNA expression profiles of a CD133+
spheroid-forming subpopulation of OVCAR3 ovarian
cancer cells were investigated to identify miRNA expres-
sion profiles that contribute toward the characteristics of
CSCs in ovarian cancer.
Results
Determination of the capacity of ovarian cancer cell lines
for in vitro anchorage-independent growth
We first tested the capacity for anchorage-independent
growth, and tumor spheroid formation was noted
in OVCAR3, TOV112D, and SKOV3 (Figure 1).
OVCAR433B and OVCAR429 did not make tumor
spheroids in the non-adherent culture system. Stringent,
low-density culture systems gave rise to tumor sphere
formation. Tumor spheres tend to grow within a week
as multi-cellular spheroids under non-differentiating and
non-adherent conditions, with the numbers of tumor
spheres reaching a maximum at two weeks. Tumor
spheres are small, non-adherent, compact, and non-
symmetric, and primary spheres can be enzymatically
dissociated to single cells, which in turn give rise to sec-
ondary spheres.
Increased paclitaxel resistance of ovarian cancer cells
in tumor spheroids
To evaluate whether tumor spheres demonstrate in-
creased resistance to chemotherapy, we compared cellviabilities between OVCAR3 and SKOV3 cells in a con-
ventional adherent culture system and tumor spheroids
using MTT assay. Spheroids are known to contain a
greater number of CSCs [6], and in accordance with pre-
vious observations, increased paclitaxel resistance was
noted in spherical ovarian cancer cells (Figure 2).
OVCAR3 cells in anchorage-independent culture
are enriched with CD133+
We determined the positivity of two CSC markers -
CD133 and CD44, which are known as ovarian CSC
markers (Figure 3). We found that CD133+ and CD44+
populations were enriched in tumor spheroids from
OVCAR3 and TOV112D cells. However, the CD44+ sub-
population presented major proportion in SKOV3 cells
under both conventional culture conditions and tumor
spheroids. Because the CD133+ subpopulation was the
most efficiently enriched in OVCAR3 tumor spheroids,
we then attempted to document the differential expres-
sion of miRNAs in CD133+ sphere forming subpopula-
tions in OVCAR3 cells. The average CD133 positivity of
OVCAR3 cells in a conventional adherent culture sys-
tem was 6.07 ± 2.31% while that of OVCAR3 cells in
tumor spheres was 74.02 ± 5.50% (P = 0.047).
The CD133+ spheroid forming subpopulation of the
OVCAR3 human ovarian cancer cell line over-expresses
‘stemness’ genes
Although we found that the CD133+ subpopulation was
enriched in tumor spheroids, the spheroids themselves
were comprised of various kinds of cells. Indeed, the
average purity of CD133+ cells in tumor spheroids of
OVCAR3 was 74.02 ± 5.50% according to flow cyto-
metric analysis. Therefore, we performed cell sorting
with a CD133 antibody in order to obtain a more puri-
fied subpopulation of CD133+ cells from tumor spheres
of OVCAR3 cells. We then tested the expression levels
of genes that correlate with “stemness,” namely Oct-4,
Sox-2, and Nanog, in cancer cells from adherent culture
systems, as well as CD133+ and CD133- cells from
tumor spheres.
RT-PCR analysis revealed that the mRNA expressions
of Oct-4, Sox-2, and Nanog were significantly increased
in the CD133+ tumor spheroid-forming subpopulation
of OVCAR3 cells, compared with those in cancer cells
from CD133- adherent cultured cells as well as those in
the CD133- tumor spheroid-forming subpopulation of
OVCAR3 cells (Figure 4). In accordance with RT-PCR
results, Western blot analysis showed that the protein
expressions of Oct-4 and Sox-2 were up-regulated in the
CD133+ tumor spheroid-forming subpopulation, while
the protein level of Nanog was not increased. Based on
these results, we determined that the CD133+ spheroid-
forming population of OVCAR3 cells over-expresses
Figure 1 Representative images of tumor spheres from OVCAR3, TOV112D, and SKOV3 cells in a sphere culture system with serum-
free DMEM-F12 (Invitrogen, Carlsbad, Calif., USA) supplemented with 10 ng/mL basic fibroblast growth factor (bFGF) and 20 ng/mL
epidermal growth factor (EGF) and plated in an ultra-low attachment plate.
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RT-PCR analysis revealed that the mRNA expressions
of Oct-4, Sox-2, and Nanog were significantly increased
in the CD133+ tumor spheroid-forming subpopulation
of OVCAR3 cells, compared with those in cancer cells
from CD133- adherent cultured cells as well as those in
the CD133- tumor spheroid-forming subpopulation of
OVCAR3 cells (Figure 4). In accordance with RT-PCR
results, Western blot analysis showed that the protein
expressions of Oct-4 and Sox-2 were up-regulated in the
CD133+ tumor spheroid-forming subpopulation, while
the protein level of Nanog was not increased. Based on
these results, we determined that the CD133+ spheroid-Figure 2 Increased paclitaxel resistance of OVCAR3 and SKOV3 cells i
those in a conventional adherent culture system.forming population of OVCAR3 cells over-expresses
“stemness” genes that may be associated with stem cell-
like characteristics.
MicroRNA microarray analysis
Based on the RT-PCR and Western blot analysis results,
we compared the miRNA expression profiles between
the OVCAR3 CD133+ spheroid-forming subpopulation
and OVCAR3 cells from an adherent culture system.
After cell sorting using FACSaria, the purity of this
sorted population as assessed using post-sort flow cyto-
metry was > 98% for the CD133+ fraction. Then, we
extracted miRNAs and performed miRNA microarray
analysis.n an anchorage-independent culture system compared with
Figure 3 Flow cytometry analysis with OVCAR3, SKOV3, and TOV-112D were performed before and after anchorage-independent
culture at least three times. CD133+ and CD44+ populations were enriched in a sphere culture system in TOV112D and OVCAR3 cells;
however, CD44+ populations were initially high in the SKOV3 cell line.
Figure 4 RT-PCR and Western blot analysis showed that a CD133+ spheroid-forming subpopulation of OVCAR3 over-expresses
“stemness” genes, compared to the levels of cancer cells from an adherent culture system as well as those from a CD133- spheroid-
forming subpopulation of OVCAR3 cells.
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tially expressed between the CD133+ spheroid-forming
subpopulation of OVCAR3 cells and those grown in
adherent cell culture. Thirty-four miRNAs including
miR-205, miR-146a, miR-200a, miR-200b, and miR-31
were significantly up-regulated, while 3 microRNAs
including miR-1202 and miR-1181 were significantly
down-regulated (Figure 5, Table 1).
Validation of microRNA results
To validate the microarray results, qRT-PCR was per-
formed with seven miRNAs that exhibited a > two-fold
change in expression (Table 2). In agreement with the
microarray results, miR-205, miR-146a, miR-200a, miR-
200b, and miR-31 were up-regulated, whereas miR-1202
and miR-1181 were down-regulated in the CD133+
spheroid-forming subpopulation (Table 2). Overall, theFigure 5 Unsupervised hierarchical clustering analysis of miRNAs tha
spheroid-forming subpopulation of the OVCAR3 human ovarian cancmicroarray data were considered sufficient to warrant
further analyses in a clinical setting.
Discussion
This study showed that a CD133+ sphere-forming sub-
population of OVCAR3 cells had a distinct microRNA
expression profile compared with that of OVCAR3 cells
grown in adherent culture conditions. These findings
might contribute to understanding miRNA-driven path-
ways related to chemoresistance in ovarian cancer.
Initially, we tested whether various ovarian cancer cell
lines can make tumor sphere. Interestingly, tumor
spheres were observed in OVCAR3, SKOV3, and
TOV112D cells. Previous studies revealed that a small
subpopulation of CSCs exists within tumor spheres [13].
MTT assay showed that tumor spheres from the
OVCAR3 and SKOV3 cells were resistant to paclitaxel.t exhibited a > two-fold increase or decrease in the CD133+
er cell line.
Table 1 Differentially expressed miRNAs with > 2-fold
change in a CD133+ spheroid forming subpopulation versus
cancer cells with conventional adherent culture conditions
miRNA Welch t-testP-value Fold change
hsa-miR-205 0.00127 11.7804
hsa-miR-146a 0.000693 7.33415
hsa-miR-193a-3p 0.00384 4.31891
hsa-miR-494 0.00879 3.94522
hsa-miR-135b 0.00368 3.39828
hsa-miR-96 0.00403 2.89271
hsa-miR-424 0.00456 2.83982
hsa-miR-365 0.00563 2.79782
hsa-miR-886-3p 0.00261 2.72994
hsa-miR-340 0.0029 2.66247
hsa-miR-210 0.00385 2.61775
hsa-miR-517a 0.0196 2.60692
hsa-miR-200a 0.0265 2.45554
hsa-miR-521 0.00856 2.42654
hsa-miR-26b 0.0207 2.41395
hsa-miR-517c 0.0254 2.38547
hsa-miR-21 0.013 2.37583
hsa-miR-31 0.0247 2.34642
hsa-miR-7 0.000204 2.32079
hsa-miR-29b 0.01 2.31852
hsa-miR-522 0.00152 2.29752
hsa-miR-516a-5p 0.0101 2.29596
hsa-miR-33a 0.0255 2.28197
hsa-miR-183 0.000939 2.25637
hsa-miR-340* 2.43E-05 2.2503
hsa-miR-449a 0.00276 2.1729
hsa-miR-200b 0.0143 2.13023
hsa-miR-455-3p 0.00331 2.10618
hsa-miR-425 0.00889 2.05804
hsa-miR-181a 0.00688 2.05351
hsa-miR-34a 0.00155 2.0393
hsa-miR-100 0.00509 2.02263
hsa-let-7f 0.0193 2.01977
hsa-miR-107 0.0182 2.00025
hsa-miR-1202 0.0134 0.41997
hsa-miR-1181 0.023 0.47041
hsa-miR-1207-5p 0.00905 0.49464
Table 2 Validation of miRNA microarray results using
quantitative RT-PCR: miRNAs differentially expressed
between OVCAR3 cells from the CD133+ sphere-forming
subpopulation compared with cells cultured in a
conventional adherent environment
MicroRNA microarray qRT-PCR
Fold change P value Fold change (mean ± SD)
has-miR-205 11.78 0.001 11.76 ± 1.32
has-miR-146a 7.33 <0.001 5.19 ± 4.14
has-miR-200a 2.45 0.0265 2.21 ± 2.54
has-miR-200b 2.13 0.014 1.81 ± 0.54
has-miR-31 2.35 0.024 2.45 ± 1.59
has-miR-1202 0.41 0.013 0.58 ± 0.22
has-miR-1181 0.47 0.023 0.67 ± 0.28
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spheres may contain an increased proportion of CSCs.
On the other hand, there is a possibility that these find-
ings could also be partly explained by the phenomenon
of a worse drug penetration into the inner layer of thespheroid as compared to monolayer cultures. Therefore,
we tested whether spheroid-forming cells express stem
cell-associated surface markers. Reproducible isolation
using distinct cell surface antigens is now regarded as a
required characteristic of CSCs [14]. Importantly,
enrichment of the cell surface marker CD133+ was
observed in tumor spheres, which shows that spheroids
contain more CSCs than adherent cultures. However,
CD44+ cells were initially high in the SKOV3 cell line in
the conventional culture system. Curley and colleagues
showed a relatively high tumorigenic potential of CD133
+ cells derived from primary human ovarian tumors in
an in vivo serial transplantation model [7]. Likewise, Fer-
randina and colleagues reported that CD133+ ovarian
tumor cells exhibited higher clonogenic efficiency com-
pared with that of CD133- cells [15]. Therefore, these
results suggest that CD133 may be a good marker for
identifying ovarian CSC populations in vitro. Then, for
miRNA expression analysis, we picked the OVCAR3 cell
line because the CD133+ subpopulation was the most
efficiently enriched in OVCAR3 cells with the sphere
culture system.
Then, the expression of genes specific to embryonic
stem cells was examined in spheroids. Poorly differen-
tiated tumors exhibit over-expression of genes that are
normally enriched in embryonic stem cells [16]. We
measured the expressions of the Oct-4, Sox-2, and
Nanog using RT-PCR and Western blot analysis. Intrigu-
ingly, the over-expressions of stem cell-related genes
were noted in CD133+ spheroid-forming populations of
OVCAR3 cells, but not in a CD133- spheroid-forming
subpopulation or in cancer cells grown in adherent cul-
ture conditions. These results suggest that only CD133+
spheroid-forming cells are associated with the expres-
sions of stem cell-related genes and presumably have
stem cell-like properties.
Therefore, we sorted CD133+ cells from tumor spheres
using a FACSAria flow cytometer for miRNA analysis. In
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tially expressed in CD133+ spheroid-forming cells com-
pared with the levels in cancer cells in conventional
adherent culture conditions of OVCAR3. These miRNAs
may be associated with stem cell-like characteristics of
ovarian cancer stem cells. While our manuscript was
under review, a study of miRNA expression profiling the
CD133+ subpopulation of OVCAR3 was published by
Guo and colleagues [12]. They found that the expres-
sions of 40 miRNAs were > two-fold higher and those of
112 miRNAs were > two-fold lower in CD133+ cells
compared to those in CD133- cells. They showed up-
regulation of the expressions of miR-204 and miR-206
and down-regulation of miR-9, miR-100, miR-223, and
miR-200c in CD133+ cells using RT PCR. However, their
results were not consistent with our miRNA expression
profiling results.
We speculate that this contradiction may be explained
by differences in the methods used to expand the CSC
population prior to sorting. We enriched CD133+ cells
using a tumor sphere assay; however, Guo and collea-
gues sorted CD133 cells using FACS only. Differences in
culture conditions may have also affected miRNA micro-
array results. Ince and colleagues used differential cul-
ture methods to isolate two separate cell populations
from the same initial source [17]. The two populations
had differential tumorigenic potential following injection
into immunocompromised mice and generated histolo-
gically different tumors with distinct metastatic poten-
tial. Taken together, these data suggest that the
characteristics of putative CSCs may vary depending on
the techniques used to isolate the CSCs. Indeed, it is
becoming evident that more stringent and clear meth-
odologies for the isolation of CSCs should be developed.
The limitation of this study is that only one cell line-
OVCAR3 was used to analyze miRNA expression pat-
terns for CD133+ spheroid forming subpopulations.
Therefore, we should note that differential expression
patterns of miRNAs in CSCs of OVCAR3 cells in this
study are not applicable for ovarian cancer in general.
However, it is worth noting the reason why only one cell
line was chosen for miRNA analysis. During this work,
we found that various cell lines from single organ ovary
could have differential stem cell characteristics.
In the present study, miR-205 was present at a level of
approximately 10-fold higher in a CD133+ spheroid-
forming subpopulation of OVCAR3 cells compared with
the levels in cells in the adherent culture condition.
Recent studies have demonstrated that miR-205 has a
role in both normal and cancer development, but these
results are controversial. Specifically, the expression of
miR-205 is significantly suppressed in ovarian cancer
[18], whereas miR-205 is significantly up-regulated in
bladder cancer [19]. Inhibition of the Src family cancause cell cycle arrest and growth suppression of ovarian
cancer cells, which may paradoxically result in chemo-
resistant characteristics of ovarian CSCs. Additionally,
miR-205 was found to be highly expressed in stem cell-
rich populations and thus may have a function in normal
mammary stem cell maintenance [20]. However, down-
regulation of miR-205 was noted in prostate cancer cell
lines resistant to chemotherapy [21].
MiR-146a was second most differentially expressed
(7.33 fold) in CD133+ spheroid-forming subpopulations
of OVCAR3 cells. This miRNA is mainly expressed in
primitive hematopoietic stem cells and T lymphocytes
[22]. Reduced expression of miR-146a in pancreatic can-
cer cells was observed compared with the level in nor-
mal human pancreatic duct epithelial cells [23]. On the
other hand, higher expression of miR-146a in NK/T cell
lymphoma demonstrated better prognosis [24]. Taken
together, further studies are needed to validate whether
these miRNAs are associated with chemo-resistance and
regulation of CSC function.
Conclusions
In conclusion, our results indicate that dysregulation of
miRNA may play a role in the stem cell-like properties
of ovarian CSCs. We are currently working to determine
the possible role of individual miRNAs in chemoresis-
tance, which will provide insight into the relevant
molecular targets for therapeutic intervention and the
eventual development of more intelligent treatment stra-
tegies for chemo-resistant ovarian cancer.
Methods
The experimental protocol was approved by the 85
Institutional Review Board of the Yonsei University
College of Medicine (4-2010-0475).
Ovarian cancer cell line
The human epithelial ovarian cancer cell lines OVCAR3,
SKOV3, TOV112D, OVCAR443B, and OVCAR429 were
obtained from the Korean Cell Line Bank. Ovarian can-
cer cells were maintained in MEM (Life Technologies,
Inc., Grand Island, NY, USA) supplemented with 10%
fetal bovine serum and 100 μg/ml streptomycin in a
humidified 5% CO2 incubator.
Assessment of the capacity for in vitro anchorage-
independent growth
In order to assess spheroid formation, approximately 5 x
103 cells were suspended in 10 mL of serum-free
DMEM-F12 (Invitrogen, Carlsbad, Calif., USA), supple-
mented with 10 ng/mL basic fibroblast growth factor
(bFGF), 20 ng/mL epidermal growth factor (EGF) and
plated in an ultra-low attachment plate (Corning Incor-
porated Life Sciences, MA, USA) to prevent adherence.
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experiments were performed in triplicate.
MTT assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was performed as previously
described [25,26]. Briefly, cells (2 x 103 cells in 100 uL
per well) were plated in 96-well plates (flat-bottomed
plate, Nunc, Naperville, IL, USA) and incubated with
serially diluted paclitaxel containing media. Cell viabil-
ities were determined after 48, 72, and 96 hours.
FACS
Cells were separated by treatment with 0.25% trypsin/
EDTA (Invitrogen, Carlsbad, Calif., USA) and washed
once with PBS. After incubation with anti-CD133-PE
(Miltenyi Biotech, Auburn, CA, USA) and anti-CD44-
FITC (eBioscience, Inc., a San Diego, USA) for 30 min
on ice in the dark, the cells were washed twice with 1 ml
of ice-cold FACS buffer and centrifuged (400x g) for
5 min at 4°C. Cells were then re-suspended in 5 ml of
PBS with 2% fetal bovine and analyzed on a FACSCali-
bur flow cytometer. Further sorting of the CD133+ sub-
population of cells was performed using FACSaria (BD
FACSaria II special order system, Biosciences, NJ, USA).
All flow cytometry results were obtained from two inde-
pendent experiments with samples performed in
triplicate.
Reverse transcription-PCR and quantitative real-time
RT-PCR
Total RNAs were extracted from cells using an RNA
Mini Kit (Qiagen), reverse-transcribed into cDNAs,
amplified for 30 cycles in 20 μL reactions with primers
(Additional file 1: Table S1), and PCR products were
electrophoresed on 2% agarose gels using glyceralde-
hydes 3-phosphate dehydrogenase (GAPDH) as a loa-
ding control.
For quantitative real-time reverse transcription-
polymerase chain reaction (qRT-PCR), we isolated total
miRNAs from cells according to previously described
methods [27] using a mirVANA microRNA Isolation Kit
(Ambion, Austin, TX, USA) according to the manufac-
turer’s protocol. Then, cDNAs were synthesized using
TaqMan MicroRNA Assays (Applied Biosystems, Foster
City, CA, USA). RT-PCR was performed using an
Applied Biosystems Prism 7500 Fast Sequence Detection
System (Applied Biosystems, Warrington, UK) according
to the manufacture’s protocol. All experiments were
repeated three times.
Protein isolation and western blot analysis
Sorted cells were lysed in a lysis buffer containing
50 mM Tris·HCl (pH 7.4), 150 mM NaCl, and 1% TritonX-100. Proteins were separated using 10% sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under denaturing conditions and were trans-
ferred to nitrocellulose membranes. The membranes
were incubated with anti-Sox2 (1:250; Abcam, Cam-
bridge, MA, USA), anti-Oct-4 (1:1000: Cell Signaling
Technology, Inc, USA), anti-Nanog (1:2000; Cell Signal-
ing Technology, Inc., USA), and anti-tubulin primary
antibodies (1:2000 Abcam, Cambridge, MA, USA) fol-
lowed by either an anti-rabbit or anti-mouse secondary
antibody conjugated with horseradish peroxidase
(1:5,000; Abcam, Cambridge, MA, USA). Antigen-
antibody complexes were detected with an ECL chemilu-
minescence detection system (Amersham, Arlington
Heights, IL, USA).
MicroRNA microarray analysis
A total RNA sample (100 ng) containing miRNA was
labeled with Cyanine 3-pGp (Cy3) using an Agilent
miRNA Complete Labeling and Hyb Kit (Agilent Tech-
nologies, CA, USA). The sample was placed on an
Agilent Human miRNA v14 chip (AMDID 029297) and
covered with a Gasket slide (Agilent Technologies, CA,
USA). Slides were hybridized for 16 hours at 42°C in an
Agilent hybridization system. MicroRNA arrays were
analyzed using GeneSpring GX v11.5 (Agilent Technolo-
gies, CA, USA) with the standard normalization method
for one-channel microarrays with the percentile median
normalization method. Fold-change values were calcu-
lated for unpaired comparisons between normal and test
samples and then averaged to generate a mean fold-
change value. Welch's t-test was used to determine sig-
nificant changes. Target predictions of significantly chan-
ged miRNAs were analyzed using TargetScan 5.1 and
miRBase v16 databases.
Statistical analysis
All experiments were carried out in triplicate. Data are
expressed as mean ± standard deviation of at least three
independent experiments. The significance of differences
was determined using Student’s t-test (Version 18.0,
SPSS, Inc., USA).
Additional file
Additional file 1: Table S1. PCR Primers.
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